Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Endothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonism.

Trow TK, Taichman DB.

Respir Med. 2009 Jul;103(7):951-62. doi: 10.1016/j.rmed.2009.02.016. Epub 2009 Mar 21. Review. Erratum in: Respir Med.2013 Sep;107(9):1463.

2.

Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?

Jacobs A, Preston IR, Gomberg-Maitland M.

Curr Med Res Opin. 2006 Dec;22(12):2567-74. Review.

PMID:
17166339
3.

Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors.

Iglarz M, Steiner P, Wanner D, Rey M, Hess P, Clozel M.

J Cardiovasc Pharmacol. 2015 Oct;66(4):332-7. doi: 10.1097/FJC.0000000000000283.

4.

Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.

Hall SM, Davie N, Klein N, Haworth SG.

Eur Respir J. 2011 Oct;38(4):851-60. doi: 10.1183/09031936.00167010. Epub 2011 Mar 15.

5.

Endothelin receptor antagonists in pulmonary arterial hypertension.

Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ.

J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):62S-67S. Review.

6.

The endothelin system in pulmonary arterial hypertension.

Galié N, Manes A, Branzi A.

Cardiovasc Res. 2004 Feb 1;61(2):227-37. Review.

PMID:
14736539
7.

The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies.

Davie NJ, Schermuly RT, Weissmann N, Grimminger F, Ghofrani HA.

Eur J Clin Invest. 2009 Jun;39 Suppl 2:38-49. doi: 10.1111/j.1365-2362.2009.02120.x. Review. Erratum in: Eur J Clin Invest. 2009 Jul;39(7):630.

PMID:
19335746
8.

Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.

Opitz CF, Ewert R.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:1-9. Review.

PMID:
16919004
9.

Endothelin(A)-endothelin(B) receptor cross-talk and endothelin receptor binding.

Rapoport RM, Zuccarello M.

J Pharm Pharmacol. 2011 Nov;63(11):1373-7. doi: 10.1111/j.2042-7158.2011.01334.x. Epub 2011 Jul 19. Review.

PMID:
21988418
10.

The importance of endothelin-1 for vascular dysfunction in cardiovascular disease.

Böhm F, Pernow J.

Cardiovasc Res. 2007 Oct 1;76(1):8-18. Epub 2007 Jun 16. Review.

PMID:
17617392
11.

Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.

Spieker LE, Noll G, Lüscher TF.

Am J Cardiovasc Drugs. 2001;1(4):293-303. Review.

PMID:
14728028
12.

Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.

Feng HQ, Weymouth ND, Rockey DC.

Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G27-33. doi: 10.1152/ajpgi.90405.2008. Epub 2009 Mar 19.

13.

Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.

Maron BA, Zhang YY, White K, Chan SY, Handy DE, Mahoney CE, Loscalzo J, Leopold JA.

Circulation. 2012 Aug 21;126(8):963-74. doi: 10.1161/CIRCULATIONAHA.112.094722. Epub 2012 Jul 11.

14.

Renal and systemic effects of chronic blockade of ET(A) or ET(B) receptors in normal rats and animals with experimental heart failure.

Francis B, Winaver J, Karram T, Hoffman A, Abassi Z.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S54-8.

PMID:
15838359
15.

Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions.

Sauvageau S, Thorin E, Caron A, Dupuis J.

J Vasc Res. 2007;44(5):375-81. Epub 2007 May 8.

PMID:
17495482
16.

Endothelin(A)-endothelin(B) receptor cross talk in endothelin-1-induced contraction of smooth muscle.

Rapoport RM, Zuccarello M.

J Cardiovasc Pharmacol. 2012 Nov;60(5):483-94. doi: 10.1097/FJC.0b013e31826f32c1. Review.

PMID:
22987051
17.

Endothelin antagonists in hypertension and kidney disease.

Meyers KE, Sethna C.

Pediatr Nephrol. 2013 May;28(5):711-20. doi: 10.1007/s00467-012-2316-4. Epub 2012 Oct 16. Review.

PMID:
23070275
18.

Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence.

Neuhofer W, Pittrow D.

Eur J Clin Invest. 2009 Jun;39 Suppl 2:50-67. doi: 10.1111/j.1365-2362.2009.02121.x. Review. Erratum in: Eur J Clin Invest. 2009 Jul;39(7):630.

PMID:
19335747
19.

Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction.

Sauvageau S, Thorin E, Caron A, Dupuis J.

Exp Biol Med (Maywood). 2006 Jun;231(6):840-6.

PMID:
16741009
20.

Endothelin receptor-mediated vasodilatation: effects of organ culture.

Nilsson D, Wackenfors A, Gustafsson L, Ugander M, Paulsson P, Ingemansson R, Edvinsson L, Malmsjö M.

Eur J Pharmacol. 2008 Jan 28;579(1-3):233-40. Epub 2007 Oct 3.

PMID:
17964568

Supplemental Content

Support Center